Bhatia · Journal of the American Heart Association 2024 · propensity score-matched prospective cohort study · n=2183

Aspirin and Cardiovascular Risk in Individuals With Elevated Lipoprotein(a): The Multi-Ethnic Study of Atherosclerosis.

Cited 75 times in the scientific literature.

Level 3 - non-randomized controlled study

Propensity score-matched prospective cohort study

PubMed 38293935 · doi:10.1161/JAHA.123.033562 · record verified 2026-08-27

What was done

Researchers analyzed data from the prospective Multi-Ethnic Study of Atherosclerosis (MESA) cohort among individuals free of baseline cardiovascular disease. Aspirin users were matched to nonusers using propensity scores based on cardiovascular disease (CVD) risk factors. The association between aspirin use and coronary heart disease (CHD) events (CHD death, nonfatal myocardial infarction) was evaluated stratified by baseline lipoprotein(a) levels (cutoff of 50 mg/dL) using multivariable Cox proportional hazards models.

What was found

After propensity matching, 2,183 participants were analyzed, of whom 1,234 (57%) used aspirin at baseline and 423 (19%) had lipoprotein(a) >50 mg/dL. Participants with lipoprotein(a) >50 mg/dL had higher incident CHD event rates than those with <=50 mg/dL (13.7% vs 8.9%, P < 0.01) and more baseline aspirin use (61.7% vs 55.3%, P = 0.02). Among participants with lipoprotein(a) >50 mg/dL, aspirin use was associated with significantly fewer CHD events (hazard ratio, 0.54 [95% CI, 0.32-0.94]; P = 0.03), bringing their risk down to a level similar to participants with lipoprotein(a) <=50 mg/dL regardless of aspirin use.

Why it matters

Elevated lipoprotein(a) lacks targeted primary prevention therapies; these findings suggest that aspirin may reduce atherothrombotic risk in this high-risk population.

Limits

The study is observational and prone to residual confounding by indication despite propensity score matching. Bleeding risks, specific aspirin dosing, and adherence changes over time were not reported in the abstract, and the subgroup with elevated lipoprotein(a) was relatively small (n = 423).

Cited by